Vertex – 2026Q1 results
Vertex Pharmaceuticals (VRTX) Q1 2026 Financial Summary Financial Highlights Business Highlights The company maintained steady performance, driven by the strong sales of its cystic fibrosis (CF) portfolio, alongside initial contributions from new product launches, specifically CASGEVY and JOURNAVX. While total revenue for the quarter missed the consensus estimate of 3.03B USD, the company demonstrated robust […]
Vertex Pharmaceuticals – History and Competitions
Vertex Pharmaceuticals’ history can be categorized into four distinct phases: 1. Founding and Rational Drug Design (1989-2000) Founded in 1989 in Boston by Dr. Joshua Boger, the company was built on the premise of “rational drug design,” using structural biology and computational chemistry to target disease mechanisms directly rather than relying on traditional random screening. […]